Payment overview · 2025
General Payments
$945.86
33 reported records · 18 companies
Healthcare provider profile · identity verified
Larry C Hollenbeck, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · NORTH KANSAS CITY, MO · NPI 1801857891
Verified facts
What the public records show
CMS Open Payments records show Larry C Hollenbeck, MD received $945.86 in general payments during 2025 across 33 reported records.
Vanda Pharmaceuticals Inc. accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Botox by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rytary by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $164.75 | 17.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.01 | 15.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $104.50 | 11.1% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $67.83 | 7.2% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $66.08 | 7.0% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $51.89 | 5.5% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $50.92 | 5.4% | 3 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $41.95 | 4.4% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $37.81 | 4.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.39 | 3.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $28.85 | 3.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $27.70 | 2.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.41 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.89 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.91 | 2.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.52 | 2.2% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $19.00 | 2.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.45 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $945.86 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $164.75 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $142.01 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $67.83 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $63.34 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $50.92 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $43.38 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $41.95 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $37.81 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $29.39 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $28.85 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 466 | 117 |
| Donepezil Hcl | Donepezil Hcl | 327 | 79 |
| Levetiracetam | Levetiracetam | 313 | 56 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 237 | 62 |
| Memantine Hcl | Memantine Hcl | 231 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 203 | 46 |
| Primidone | Primidone | 185 | 42 |
| Clonazepam | Clonazepam | 145 | 27 |
| Divalproex Sodium | Divalproex Sodium | 143 | suppressed |
| Pregabalin | Pregabalin | 139 | 33 |
| Topiramate | Topiramate | 127 | 34 |
| Baclofen | Baclofen | 124 | 29 |
| Propranolol Hcl | Propranolol Hcl | 117 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 26 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 105 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 93 | 13 |
| Lacosamide | Lacosamide | 91 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 13 |
| Tramadol Hcl | Tramadol Hcl | 87 | 20 |
| Carbamazepine | Carbamazepine | 84 | 17 |
| Rivastigmine | Rivastigmine Tartrate | 81 | 15 |
| Prednisone | Prednisone | 79 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 17 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 76 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 15 |
| Lamotrigine | Lamotrigine | 66 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 64 | 13 |
| Dilantin | Phenytoin Sodium Extended | 63 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 63 | 15 |
| Meloxicam | Meloxicam | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 11 |
| Sertraline Hcl | Sertraline Hcl | 53 | 11 |
| Carbamazepine Er | Carbamazepine | 49 | suppressed |
| Amantadine | Amantadine Hcl | 47 | 16 |
| Teriflunomide | Teriflunomide | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 38 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 37 | suppressed |
| Risperidone | Risperidone | 37 | suppressed |
| Alprazolam | Alprazolam | 35 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Dalfampridine Er | Dalfampridine | 26 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Rytary | Carbidopa/Levodopa | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | 14 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Vumerity | Diroximel Fumarate | 23 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Zonisamide | Zonisamide | 22 | suppressed |
| Azathioprine | Azathioprine | 20 | suppressed |
| Briviact | Brivaracetam | 20 | suppressed |
| Entacapone | Entacapone | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Botox | Onabotulinumtoxina | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Valium | Diazepam | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $945.86 · 33 records | Vanda Pharmaceuticals Inc. | ACTHAR, BOTOX, Bafiertam, CREXONT, Fintepla, INFINITY, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, Ocrevus Zunovo, PONVORY, QULIPTA, Qelbree, REXULTI, Rystiggo, Tascenso ODT, UBRELVY, VYALEV, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error